{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-105923","form_type":"8-K","ticker":"HSCS","cik":"0001468492","company_name":"HeartSciences Inc.","filed_at":"2024-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.141692+00:00","generated_at":"2026-05-31T05:13:23.097296+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"HeartSciences reports Q1 FY2025 cash of $4.3M, raises $1.9M in non-dilutive debt; MyoVista device on track","bullets":["Cash and cash equivalents of $4.3M as of July 31, 2024; shareholders' equity of $5.9M.","Subsequent to quarter end, closed $1.9M net non-dilutive 18-month loan and extended $500K loan to Sep 2025.","FDA 510(k) submission for MyoVista wavECG device remains on track for Q1 calendar 2025.","Cloud-based MyoVista Insights platform Phase 1 on track for end of calendar 2024; FDA submission target H2 2025.","No revenue reported for Q1 FY2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-105923","json":"https://secwatch.observer/filing/0000950170-24-105923.json","markdown":"https://secwatch.observer/filing/0000950170-24-105923.md","text":"https://secwatch.observer/filing/0000950170-24-105923.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468492/000095017024105923/0000950170-24-105923-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468492/000095017024105923/hscs-20240912.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:13:23.097296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}